Development of a precision Luminex-based SARS-CoV-2 assay

Purpose and goal Sweden has adopted unconventional measures to respond to the COVID-19 pandemic by relying on self-disciplined physical distancing. Determination of the degree to which the community has contracted SARS-CoV-2 infection, and developed presumptive herd immunity is hence critical. This project seeks to develop a novel precision test for SARS-CoV-2 specific antibody to help define asymptomatic cases whose immune status is unknown or may presumably be mis-diagnosed by the conventional sub-optimal serology tests. Expected results and effects It is expected that this project determine SARS-CoV-2 specific linear B cell peptides that can be used for diagnostic serology assays. Efforts will be also made to develop a standardized, high precision, multiplexed serology assay to help diagnose past and present asymptomatic SARS-CoV-2 infection. Planned approach and implementation The developed SARS-CoV-2 precision serology test will be made available for implementation, and potential integration with other SARS-CoV-2 serology testing activities, to help estimate distribution of asymptomatic SARS-CoV-2 infected cases in the community.